Biotech manager is on life support

Thu Mar 29, 2007

A struggling biotech hedge fund has offered to waive management fees in exchange for a longer lockup and higher performance fees after a year of sliding returns.

The arrangement has helped New York-based Mallette Capital Management keep onshore and offshore versions of Mallette Capital Biotech Fund open despite a 27% loss in November that dragged its full-year return down by 40%.


ISSN: 2151-1845 / CDC10004H


The full contents of this article are available to active AR subscribers and trialists only.

To continue reading please,
take a free trialsubscribe or log in to AR.


Subscribers have unlimited access to all current and archive content. Start your subscription today - click on the button below.

Subscribe now

Popular Searches on HFI